Study S002610

Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04445181
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 14873
Start: 2020-07-01
Primary completion: 2020-11-23
Lead sponsor: Bayer
Conditions: Chronic Kidney Disease in Type 2 Diabetes
Interventions: DRUG:The physician's prescription in routine clinical practice
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Proportion of patients with CKD in a large T2D population [Retrospectively analysis between January 1, 2019 and December 31, 2019]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010376	Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. Chu L, Clinical therapeutics	2021	Nonrandomized study	PMID 34426012 DOI	cites ClinicalTrials.gov:NCT04445181; registry reference DERIVED:34426012